Zydus Cadila Receives USFDA's Approval to Market Eletriptan Hydrobromide Tablets
DSIJ Intelligence / 19 Jun 2017
Cadila Healthcare on Monday informed that Zydus Cadila has received the final approval from USFDA to market Eletriptan Hydrobromide Tablets, 20 mg (base) and 40 mg (base).
Cadila Healthcare Limited, an integrated healthcare company, discovers, develops, manufactures, and markets a range of healthcare and pharmaceutical products worldwide. Cadila Healthcare on Monday informed that Zydus Cadila has received the final approval from USFDA to market Eletriptan Hydrobromide Tablets, 20 mg (base) and 40 mg (base).
The drug will be manufactured at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad. It is used in the treatment of migraine.
Meanwhile, at Rs 533 per share at 1044 hours IST on BSE, Cadila Healthcare was trading higher by 1.4%. It hit a high of Rs 538.10 and a low of Rs 527.60 so far during the morning session.
Delivering around 70% returns in a period of one year, the stock has outperformed both the BSE Sensex and BSE Healthcare over the same duration. Its closest peers are Lupin and Sun Pharmaceutical Industries.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.